Mettler Toledo (MTD)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$1345.26-0.81%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Intact: The reason to own it still holds.
Mettler Toledo grows earnings about 8% to 10% in 2026. Sales rise steadily near 4% in local currency. Profit margins stay strong with consistent beats. The company leads in weighing and analytical instruments.
Sales growth lags the 4% target and EPS growth slows below 8%. Rising costs could pressure profit margins. Competition or market softness may hurt demand and earnings.
The price is about 8% above our fair value near $1194. Analysts expect roughly 6% revenue growth, slightly below management's 8-10% EPS growth target. Our fair value is 13% below the Street median, reflecting some valuation caution.
Breaks if: adjusted EPS growth falls below 8% in FY26
Breaks if: local currency sales growth falls below 3% in FY26
Spinnaker program expansion stalls or reverses in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a durable compounder with a focus on consistent growth. The current thesis state is intact, supported by strong recent financial results and management's clear priorities.
The valuation is considered cheap compared to peers, with no significant expectations gap. The market appears to have priced in a stable outlook without indicating fragility.
Management is on track to achieve adjusted earnings per share (EPS) growth of 8% to 10% and local currency sales growth of about 4%. Recent financial performance has been strong, but there is a low probability of missing future targets.
The long-term thesis hinges on maintaining guidance and performance amid potential economic headwinds. Key factors include the performance of sector bellwethers and the overall economic environment, particularly job growth.
The most important moves since the prior daily snapshot.
Signal changed from 'favorable' to 'mild_favorable'.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Leverage and expand the Spinnaker sales and marketing program to drive growth and improve market penetration across key regions and segments.
Stated as a priority in 3 of last 4 quarters. Management consistently highlights the Spinnaker program as a key driver of growth and margin expansion. While direct sales impact is not separately quantified, overall revenue and adjusted EPS growth in recent quarters align with management's emphasis on this initiative, indicating progress though specific attribution is limited.
“Benefits from our Spinnaker sales and marketing and productivity initiatives resulted in excellent Adjusted EPS growth.”
“We continue to leverage our Spinnaker sales and marketing program to drive growth.”
“Strong execution as we leverage our Spinnaker sales and marketing program and innovative product portfolio to drive growth.”
In the next 1 to 3 years, MTD's performance will depend on its ability to navigate risks while continuing to deliver on its growth targets. Not investment advice.